| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD011006 |
| P8608 | Fatcat ID | release_ayhfjddju5ge5biemo6wcsetca |
| P50 | author | Corrado Barbui | Q28037211 |
| Matthew Hotopf | Q37842347 | ||
| Faith Matcham | Q44192912 | ||
| Giovanni Ostuzzi | Q58747932 | ||
| P2093 | author name string | Sarah Dauchy | |
| P2860 | cites work | Pharmacological treatment of depression in patients with a primary brain tumour | Q24202721 |
| Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients | Q24202815 | ||
| Antidepressants for depression in physically ill people | Q24236616 | ||
| Pharmacological treatment of depression in patients with a primary brain tumour | Q24236728 | ||
| Psychotherapy for depression among incurable cancer patients | Q24243311 | ||
| Drugs versus placebo for dysthymia | Q24246945 | ||
| A rating scale for depression | Q24564540 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| An Inventory for Measuring Depression | Q26778503 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| The hospital anxiety and depression scale | Q27860968 | ||
| Evidence-based treatment of depression in patients with cancer | Q28261779 | ||
| Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature | Q29614233 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Meta-analyses involving cross-over trials: methodological issues | Q29620304 | ||
| Imputing missing standard deviations in meta-analyses can provide accurate results | Q29620610 | ||
| Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials | Q31827980 | ||
| The treatment of depression in cancer patients: a systematic review. | Q33261185 | ||
| Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology | Q33886704 | ||
| Depression and cancer mortality: a meta-analysis. | Q34112594 | ||
| Novel melatonin-based therapies: potential advances in the treatment of major depression | Q34186242 | ||
| The Functional Assessment of Cancer Therapy scale: development and validation of the general measure | Q34361336 | ||
| Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis | Q34459442 | ||
| Adjustment disorders: the state of the art | Q34623390 | ||
| The molecular neurobiology of depression. | Q36262545 | ||
| Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer | Q36790594 | ||
| Relative mortality from overdose of antidepressants | Q36902064 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes | Q37331962 | ||
| The prevalence and pharmacotherapy of depression in cancer patients | Q37781921 | ||
| Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis | Q37799171 | ||
| Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials | Q37801829 | ||
| The development of evidence-based European guidelines on the management of depression in palliative cancer care | Q37826554 | ||
| Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects | Q38049302 | ||
| Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. | Q38122158 | ||
| Depressed patients with incurable cancer: which depressive symptoms do they experience? | Q39471599 | ||
| Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis | Q39947185 | ||
| A consumer's guide to subgroup analyses | Q41111858 | ||
| Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies | Q46324032 | ||
| Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. | Q46698519 | ||
| Suicidality and its Associated Factors in Cancer Patients: Results of a Multi-Center Study in Korea | Q47820077 | ||
| Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression | Q48395582 | ||
| Quality of life of family caregivers at 2 years after a relative's cancer diagnosis | Q51870083 | ||
| Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site | Q51934097 | ||
| Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation | Q51958594 | ||
| Depression--an independent predictor of early death in patients with advanced cancer | Q81466364 | ||
| P577 | publication date | 2014-03-05 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antidepressants for the treatment of depression in patients with cancer |
| Q24187358 | Antidepressants for the treatment of depression in people with cancer | cites work | P2860 |
Search more.